Law360, New York ( July 23, 2013, 12:34 PM EDT) -- When it was signed into law by President Obama on July 12, 2012, the Food and Drug Administration Safety Information Act, Pub. L. No. 112-144, 126 Stat. 1055 (2012) (FDASIA) was best known for its five-year reauthorization of brand pharmaceuticals user fees and the creation of a new user-fee program for generic and biosimilar products. However, the FDASIA contains a number of additional provisions, some of which relate to improving patient access to medical treatments and technologies....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.